Trials / Recruiting
RecruitingNCT07160816
A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar
A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Use of Insulin Icodec in People Living With Type 1 Diabetes
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 245 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 1 diabetes (T1D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin icodec | Participants with T1D will be treated with commercially available insulin icodec. |
Timeline
- Start date
- 2025-08-28
- Primary completion
- 2027-01-20
- Completion
- 2027-01-20
- First posted
- 2025-09-08
- Last updated
- 2026-04-06
Locations
37 sites across 2 countries: Germany, Italy
Source: ClinicalTrials.gov record NCT07160816. Inclusion in this directory is not an endorsement.